By / January 15, 2020

Cannabis medication from pharmacies fell by 5% in the Netherlands

The increasing use of cannabis medication from pharmacies in the Netherlands seems to have come to an end.

In 2019, community pharmacies dispensed about 5% less cannabis medication. As a result, the number of dispensed medication fell below 50,000 for the first time since 2017. The share of medical cannabis oil dispensed by pharmacies remains the same at about 55%.

You can find more information about cannabis markets and other important news in the cannabis sector in the app. This app collects the latest cannabis news among cannabis sectors that investors operate in.

A look at cannabis medication trends in the Netherlands

The use of medical cannabis continued to increase until the first half of 2017. The number of prescriptions dispensed in 2017 was more than 53,000, an increase of 17.5% compared to the previous year.

The number of cannabis medication prescriptions fell by 4% in 2018 to more than 51,000. Based on dispensing figures of 2019, SFK expects the total for the previous year to be 48,500 pharmacy-dispensed prescriptions, a decrease of approximately 5%.

The global legal cannabis market will be worth $13,346 billion by 2019, according to the Brightfield Group, and 80% of these sales will be made in the United States.

Bedrocan faces criticism from pharmacists about cannabis medication

Whether the number of patients using cannabis medication decreases proportionally is doubtful. The SFK only measures on the basis of figures from the legal medical cannabis supply. This is done in the Netherlands under the responsibility of the Bureau Medicinale Cannabis (BMC) which falls under the Ministry of Health, Welfare and Sport.

A picture of Holland representing cannabis medication in the Netherlands
Pharmacists are seeing fewer prescriptions for cannabis medication across the Netherlands due to inconsistent product. (Source)

The BMC supervises the cultivation of medical cannabis, which is currently only done by the supplier Bedrocan. Bedrocan produces five dried varieties of cannabis with different proportions of active substances. Since 2015, some pharmacies have been using cannabis from Bedrocan to prepare cannabis medication and oils with different concentrations of THC and CBD.

There is a lot of criticism of cannabis and cannabis oil from the pharmacy. The five types of Bedrocan cannabis products are far from sufficient for the wide range of ailments in which cannabis treats.

That’s why many patients prefer to grow their own medical cannabis. This gives them ultimate control over the type of cannabis and the method of cultivation. There’s a risk involved because growing cannabis yourself is forbidden.

Local foundations help citizens get better access to cannabis

Another group of patients turns to a foundation such as Suver Nuver or SNSH. These are foundations that challenge the law to provide people with high-quality cannabis medication at the lowest possible price.

According to Rinus Beintema, founder of Suver Nuver, the number of members that buy cannabis oil from him is increasing every day.

Finally, SFK did not include the number of sales of CBD oil in its figures either. Sales of this beneficial cannabis extract without THC have risen sharply in recent years. Some pharmacies sell it, but the vast majority of CBD products are sold online or through the drugstore.

So do these figures say anything about the number of users of medical cannabis in the Netherlands? Probably little to nothing. It does suggest that the legal policy is inadequate; a problem that various experts have been raising with the government for years.


(Featured image by Add Weed via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Mediwietsite, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Comments are closed for this post.